Bleeding disorder of unknown cause (BDUC) is increasingly recognized as a common diagnosis among adult patients with mild to moderate bleeding symptoms and is reflective of unremarkable hemostatic tests despite a clinically relevant bleeding tendency. While extensive clinical and basic research has been conducted on the bleeding phenotype and underlying mechanisms of BDUC, great uncertainty remains regarding the long-term risk for spontaneous bleeding and the bleeding risk after hemostatic challenges. Currently available data suggest that a substantial portion of BDUC patients continue to experience spontaneous bleeding symptoms, such as easy bruising, epistaxis, and heavy menstrual bleeding. Risk factors associated with the persistence of these symptoms include the presence of the respective symptom prior to the BDUC diagnosis and a higher baseline bleeding score. Furthermore, a large proportion of BDUC patients report bleeding complications after surgery or child delivery prior to initial investigations. Patients with prior bleeding complications after such events, patients with blood group O, and patients who did not receive hemostatic prophylaxis demonstrate an increased risk for postinterventional bleeding during follow-up. Although BDUC remains a diagnosis of exclusion, accumulating data underscore the need to recognize it as a potentially persistent clinically relevant condition. Future studies should focus on refining diagnostic algorithms, investigating underlying mechanisms, and developing predictive tools for bleeding risk to improve individualized management strategies.

1.
Rodeghiero
F
,
Tosetto
A
,
Abshire
T
, et al
;
International Society on Thrombosis and Haemostasis/SSC joint von Willebrand Factor and Perinatal/Pediatric Hemostasis Subcommittees Working Group
.
ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders
.
J Thromb Haemost
.
2010
;
8
(
9
):
2063
-
2065
.
2.
Baker
RI
,
Choi
P
,
Curry
N
, et al
;
International Society on Thrombosis and Haemostasis SSC Von Willebrand Factor, Platelet Physiology, and Women's Health Issues in Thrombosis and Haemostasis
.
Standardization of definition and management for bleeding disorder of unknown cause: communication from the SSC of the ISTH
.
J Thromb Haemost
.
2024
;
22
(
7
):
2059
-
2070
.
3.
Doherty
D
,
Grabell
J
,
Christopherson
PA
, et al
;
Zimmerman Program Investigators
.
Variability in International Society on Thrombosis and Haemostasis-Scientific and Standardization Committee endorsed Bleeding Assessment Tool (ISTH-BAT) score with normal aging in healthy females: contributory factors and clinical significance
.
J Thromb Haemost
.
2023
;
21
(
4
):
880
-
886
.
4.
Mehic
D
,
Pabinger
I
,
Gebhart
J
.
Investigating patients for bleeding disorders when most of the “usual” ones have been ruled out
.
Res Pract Thromb Haemost
.
2023
;
7
(
8
):
102242
.
5.
Hansen
RS
,
Carlsen
M
,
Rasmussen
KF
,
Vinholt
PJ
.
Translation, validation, and usability of the International Society on Thrombosis and Haemostasis Bleeding Assessment Tool (Self-ISTH-BAT)
.
Eur J Haematol
.
2021
;
107
(
1
):
104
-
110
.
6.
Königsbrügge
O
,
Meisel
H
,
Beyer
A
, et al
.
Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: from the VIVALDI, a population-based prospective cohort study
.
J Thromb Haemost
.
2021
;
19
(
12
):
2984
-
2996
.
7.
Englisch
C
,
Moik
F
,
Steiner
D
, et al
.
Bleeding events in patients with cancer: incidence, risk factors, and impact on prognosis in a prospective cohort study
.
Blood
.
2024
;
144
(
22
):
2349
-
2359
.
8.
Mai
V
,
Guay
CA
,
Perreault
L
, et al
.
Extended anticoagulation for VTE: a systematic review and meta-analysis
.
Chest
.
2019
;
155
(
6
):
1199
-
1216
.
9.
Mehic
D
,
Schwarz
S
,
Shulym
I
,
Ay
C
,
Pabinger
I
,
Gebhart
J
.
Health-related quality of life is impaired in bleeding disorders of unknown cause: results from the Vienna Bleeding Biobank
.
Res Pract Thromb Haemost
.
2023
;
7
(
6
):
102176
.
10.
Fasulo
MR
,
Biguzzi
E
,
Abbattista
M
, et al
.
The ISTH Bleeding Assessment Tool and the risk of future bleeding
.
J Thromb Haemost
.
2018
;
16
(
1
):
125
-
130
.
11.
Mehic
D
,
Neubauer
G
,
Janig
F
, et al
.
Risk factors for future bleeding in patients with mild bleeding disorders: longitudinal data from the Vienna Bleeding Biobank
.
J Thromb Haemost
.
2023
;
21
(
7
):
1757
-
1768
.
12.
Berkowitz
C
,
Ma
A
,
Miller
V
, et al
.
Periprocedural hemostatic prophylaxis and outcomes in bleeding disorder of unknown cause
.
Res Pract Thromb Haemost
.
2024
;
8
(
7
):
102572
.
13.
Relke
N
,
Kuthiala
S
,
Grabell
J
,
Hopman
WM
,
James
P.
The bleeding score: useful in predicting spontaneous bleeding events in adults with bleeding of unknown cause?
Haemophilia
.
2020
;
26
(
2
):
e31
-
e33
.
14.
Castle
D
,
Desborough
MJR
,
Kemp
M
,
Lowe
G
,
Thomas
W
,
Obaji
S.
Outcomes and management of pregnancy in women with bleeding disorder of unknown cause
.
J Thromb Haemost
.
2022
;
20
(
11
):
2519
-
2525
.
15.
Obaji
S
,
Alikhan
R
,
Rayment
R
,
Carter
P
,
Macartney
N
,
Collins
P.
Unclassified bleeding disorders: outcome of haemostatic challenges following tranexamic acid and/or desmopressin
.
Haemophilia
.
2016
;
22
(
2
):
285
-
291
.
16.
Zafarani
A
,
Ghodratnia
E
,
Amirzargar
MR
, et al
.
Bleeding disorder of unknown cause: results from Iranian study
.
Transfus Apher Sci
.
2023
;
62
(
5
):
103730
.
17.
Monard
ALL
,
Mussert
CMA
,
Van Duijl
TT
, et al
.
Bleeding disorder of unknown cause: an illustrated review on current practice, knowledge gaps, and future perspectives
.
Res Pract Thromb Haemost
.
2024
;
8
(
8
):
102625
.
18.
MacDonald
S
,
Wright
A
,
Beuche
F
, et al
.
Characterization of a large cohort of patients with unclassified bleeding disorder: clinical features, management of haemostatic challenges and use of global haemostatic assessment with proposed recommendations for diagnosis and treatment
.
Int J Lab Hematol
.
2020
;
42
(
2
):
116
-
125
.
19.
Gebhart
J
,
Hofer
S
,
Panzer
S
, et al
.
High proportion of patients with bleeding of unknown cause in persons with a mild-to-moderate bleeding tendency: results from the Vienna Bleeding Biobank (VIBB)
.
Haemophilia
.
2018
;
24
(
3
):
405
-
413
.
20.
Karlsson
TS
,
Marions
LB
,
Edlund
MG
.
Heavy menstrual bleeding significantly affects quality of life
.
Acta Obstet Gynecol Scand
.
2014
;
93
(
1
):
52
-
57
.
21.
Kaatz
S
,
Ahmad
D
,
Spyropoulos
AC
,
Schulman
S
;
Subcommittee on Control of Anticoagulation
.
Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH
.
J Thromb Haemost
.
2015
;
13
(
11
):
2119
-
2126
.
22.
Rodeghiero
F
,
Castaman
G
,
Tosetto
A
, et al
.
The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study
.
J Thromb Haemost
.
2005
;
3
(
12
):
2619
-
2626
.
23.
MacLean
B
,
Fuller
J
,
Lim
J
,
Dugan
C
,
Richards
T.
Greater prevalence of anaemia and heavy menstrual bleeding reported in women of reproductive age in the United Kingdom compared to Australia
.
Br J Haematol
.
2025
;
206
(
5
):
1479
-
1484
.
24.
Curry
N
,
Bowles
L
,
Clark
TJ
, et al
.
Gynaecological management of women with inherited bleeding disorders. A UK Haemophilia Centres Doctors' Organisation Guideline
.
Haemophilia
.
2022
;
28
(
6
):
917
-
937
.
25.
Kelly
C
,
Thomas
W
,
Baker
RI
,
O'Donnell
JS
,
Sanchez-Luceros
A
,
Lavin
M.
Examining variability in the diagnosis and management of people with bleeding disorders of unknown cause: communication from the ISTH SSC Subcommittee on von Willebrand Factor
.
J Thromb Haemost
.
2024
;
22
(
10
):
2900
-
2909
.
26.
Quiroga
T
,
Goycoolea
M
,
Panes
O
, et al
.
High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls
.
Haematologica
.
2007
;
92
(
3
):
357
-
365
.
27.
Atiq
F
,
Blok
R
,
Van Kwawegen
CB
, et al
.
Clinical phenotype and pathophysiological mechanisms underlying qualitative low VWF
.
Blood
.
2025
;
146
(
3
):
369
-
381
.
28.
O'Donnell
JS
,
Baker
RI
.
Low von Willebrand disease: a bleeding disorder of unknown cause?
Hamostaseologie
.
2023
;
43
(
1
):
44
-
51
.
29.
Jiménez-Yuste
V.
Non-factor therapies for hemophilia: achievements and perspectives
.
Semin Thromb Hemost
.
2025
;
51
(
1
):
23
-
27
.
30.
James
PD
,
Connell
NT
,
Ameer
B
, et al
.
ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease
.
Blood Adv
.
2021
;
5
(
1
):
280
-
300
.
You do not currently have access to this content.